NYSE: RMD · Industrial Applications and Services · 6 alerts · CIK 943819
Share price
$238.19Close, Nov 16
Market cap
$33.5B
Shares outstanding
140.66MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Resmed Inc filings on SEC EDGAR ↗
Resmed Chairman and CEO Michael J. Farrell Sells $1.18M of Stock
Michael J. Farrell, Chairman and CEO, sold 4,993 shares of Resmed Inc at $235.35 a share, worth $1.18M in total on Nov 9, 2026. Shares held after the trade: 479,803 (-1.0%).
ResMed Inc. reported a net revenue increase to $1.41 billion for the quarter ended September 30, 2026, compared to $1.34 billion in the prior year, driven by Sleep and Breathing Health products. Net income rose to $418.4 million, significantly aided by a $61.8 million gain from the divestment of subsidiaries.
ResMed delivered strong FY2026 results with 10% revenue growth and introduced FY2027 guidance, balancing core sleep growth against a $75 million headwind from the Astral field safety action.
ResMed reported Q1 fiscal year 2027 revenue of $1.4 billion, a 6% increase driven by global demand for sleep and breathing health solutions. The company returned over $1 billion to shareholders through dividends and share repurchases during the quarter, supported by strong free cash flow and the divestiture of MatrixCare.
Term
Q1 2027
“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business. Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%.”
Mick Farrell, Resmed’s Chairman and CEO
“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”
Resmed Global General Counsel Michael J. Rider Sells $102K of Stock
Michael J. Rider, Global General Counsel, sold 400 shares of Resmed Inc at $255.00 a share, worth $102K in total on Oct 23, 2026. Shares held after the trade: 12,318 (-3.1%).